310 related articles for article (PubMed ID: 16406782)
1. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
2. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Hurt DE; Widom J; Clardy J
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):312-23. PubMed ID: 16510978
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Boa AN; Canavan SP; Hirst PR; Ramsey C; Stead AM; McConkey GA
Bioorg Med Chem; 2005 Mar; 13(6):1945-67. PubMed ID: 15727850
[TBL] [Abstract][Full Text] [Related]
4. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites.
Walse B; Dufe VT; Svensson B; Fritzson I; Dahlberg L; Khairoullina A; Wellmar U; Al-Karadaghi S
Biochemistry; 2008 Aug; 47(34):8929-36. PubMed ID: 18672895
[TBL] [Abstract][Full Text] [Related]
5. New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold.
Lolli ML; Giorgis M; Tosco P; Foti A; Fruttero R; Gasco A
Eur J Med Chem; 2012 Mar; 49():102-9. PubMed ID: 22245049
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans.
Zameitat E; Gojković Z; Knecht W; Piskur J; Löffler M
FEBS J; 2006 Jul; 273(14):3183-91. PubMed ID: 16774642
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
9. Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.
Malmquist NA; Gujjar R; Rathod PK; Phillips MA
Biochemistry; 2008 Feb; 47(8):2466-75. PubMed ID: 18225919
[TBL] [Abstract][Full Text] [Related]
10. Biaryl analogues of teriflunomide as potent DHODH inhibitors.
Erra M; Moreno I; Sanahuja J; Andrés M; Reinoso RF; Lozoya E; Pizcueta P; Godessart N; Castro-Palomino JC
Bioorg Med Chem Lett; 2011 Dec; 21(24):7268-72. PubMed ID: 22078215
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain.
Pinheiro MP; Iulek J; Cristina Nonato M
Biochem Biophys Res Commun; 2008 May; 369(3):812-7. PubMed ID: 18302934
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
[TBL] [Abstract][Full Text] [Related]
13. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
14. An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase.
M S; B P; Swaminathan P
Curr Comput Aided Drug Des; 2020; 16(3):340-350. PubMed ID: 31132976
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
[TBL] [Abstract][Full Text] [Related]
16. Dual binding mode of a novel series of DHODH inhibitors.
Baumgartner R; Walloschek M; Kralik M; Gotschlich A; Tasler S; Mies J; Leban J
J Med Chem; 2006 Feb; 49(4):1239-47. PubMed ID: 16480261
[TBL] [Abstract][Full Text] [Related]
17. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Heikkilä T; Thirumalairajan S; Davies M; Parsons MR; McConkey AG; Fishwick CW; Johnson AP
Bioorg Med Chem Lett; 2006 Jan; 16(1):88-92. PubMed ID: 16236496
[TBL] [Abstract][Full Text] [Related]
18. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
Lucas-Hourani M; Munier-Lehmann H; El Mazouni F; Malmquist NA; Harpon J; Coutant EP; Guillou S; Helynck O; Noel A; Scherf A; Phillips MA; Tangy F; Vidalain PO; Janin YL
J Med Chem; 2015 Jul; 58(14):5579-98. PubMed ID: 26079043
[TBL] [Abstract][Full Text] [Related]
19. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.
Hansen M; Le Nours J; Johansson E; Antal T; Ullrich A; Löffler M; Larsen S
Protein Sci; 2004 Apr; 13(4):1031-42. PubMed ID: 15044733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]